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Background: HPV infection is an established risk factor for oropharyngeal cancer, and it has been proposed that
cigarette smoking may potentiate HPV infection in the oral epithelium. We sought to test the hypothesis that
cigarette smoking increases HPV infection in an HPV16 serology study of cancer-free individuals.
Methods: Subjects were participants in a risk factor study for head and neck cancer, and were required to have no
prior history of either HNSCC or any other cancer. Tobacco use and other risk factor data were gathered through
interviewer-assisted questionnaires, while serology was conducted in a blinded fashion using a glutathione
S-transferase capture enzyme-linked immunosorbent assay (ELISA) to detect antibodies against HPV16 L1, E1, E2, E4,
E6 and E7 proteins. The differences in tobacco use by HPV serology were evaluated by ANOVA; and the reported
odds ratios and 95% confidence intervals were determined by using unconditional logistic regression.
Results: We found no overall association of HPV16 serological markers with smoking. However, when the data
were stratified by median age, smoking was positively associated with seropositivity for the HPV16 L1 capsid
antigen in the younger controls while the older controls were less likely to be HPV16 L1 positive if they smoked
(pinteraction < 0.002). There was no similar association of smoking and age with serological response to the early
proteins (i.e E6, E7).
Conclusions: Exposure to HPV16 capsid protein (L1) is increased among relatively younger adults who smoke and
diminished among older smokers. However, this pattern is not accompanied by a differential susceptibility for active
infection (as determined by the early gene proteins such as E6 and E7) among young and older smokers.
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Human papillomavirus (HPV) is currently accepted as a
risk factor for squamous cancers of the anogenital region
and head and neck (HNSCC). HPV16 is estimated to
account for the majority of cervical cancers and approxi-
mately 90% of all of virus-positive head and neck can-
cers [1], although other high-risk HPVs are known to
cause both of these cancers [2]. HPVs show a distinct
preference for site of infection in the upper aerodigestive
tract, being most commonly associated with infection of
the base of the tongue, tonsillar bed, and oropharynx.* Correspondence: karl_kelsey@brown.edu
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unless otherwise stated.The majority of incident cancers at these sites diagnosed in
the United States today are HPV-associated, and current
trends suggest that the incidence of HPV16-positive
HNSCC will increase markedly in the near term [3].
Recent studies suggest that the population prevalence
of any oral HPV in the United States is approximately
6.9% [4], with the prevalence of high-risk HPV16 being
much less, estimated at 1-3% [4]. It is thought that most
HPV infections are transient and spontaneously resolve.
However, in a subset of individuals, high-risk HPV infec-
tion can persist, increasing the risk of viral integration into
the host DNA, which can ultimately lead to HNSCC.
There is currently considerable interest in understanding
the factors that contribute, either together or independ-
ently, to increase exposure and infection by HPV in the
oral cavity and pharynx.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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smoking is associated with enhancing HPV-positive
HNSCC [5,6], or if these risk factors are independent [7].
A related but separate question is whether smoking pro-
motes HPV infection via shared risk behaviors, or perhaps
gives rise to an altered immune response to the virus, po-
tentially leading to a longer duration of infection (poorer
clearance of the virus). Gillison et al [4,8] have recently
shown that PCR detection of HPV from oral rinse in a
subset of the National Health and Nutrition Examination
Survey (NHANES) participants was positively associated
with the current number of cigarettes smoked. At the
same time, a recent prospective study of college-age men,
using a both a measure of HPV16 serology and a method
that collected exfoliated genital cells for HPV DNA detec-
tion, reported a modest increase in seroconversion associ-
ated with smoking [9], consistent with some of the
literature [10,11]. Similarly, Kreimer et al recently showed
that smoking is associated with detectable oncogenic HPV
in oral rinses from normal men, but the incidence of
infection was low (1%) and 5 of the 6 incident infections
cleared within 12 months [12]. Others, however, have
reported conflicting results [13-15], finding little evidence
for smoking to enhance HPV infection. Given the still
conflicting findings, the association between smoking and
infection remains unclear. As these prior studies have ex-
amined the numerous different means of assessing HPV,
often using DNA-based measurements, we have taken a
more focused approach to the question and used serologic
endpoints to assess the smoking-HPV relationship.
We have examined HPV serological data in cancer-free
controls enrolled in a population-based case-control
study of HNSCC. Of interest to us was the nature of the
association of evidence of an immune response to HPV
with an individual’s history of tobacco use. We have
examined both L1 (capsid) antibodies, which are formed
after exposure to the virus and do not necessarily indicate
recent infection, as well as antibodies to early gene prod-
ucts, which effectively signal relatively recent pathological
infection, asking whether tobacco smoking is associated
with the presence of these HPV biomarkers.
Methods
Study population
Incident cases of HNSCC were enrolled through nine med-
ical facilities located in Boston, Massachusetts (Brigham
and Women's Hospital, Beth Israel Deaconess Medical
Center, Boston Veterans Administration, Boston Medical
Center, Dana-Farber Cancer Institute, Harvard Vanguard
Medical Associates, Massachusetts Eye and Ear Infirmary,
Massachusetts General Hospital, and New England Medical
Center) as part of a population-based case-control study of
head and neck cancer in the greater-Boston area [7]. Con-
trol subjects with no prior history of either HNSCC or anyother cancer were selected using town records and
frequency-matched to cases on age (+/- 3 years), sex,
and neighborhood/town of residence. The study in-
cludes data collected from two periods of recruitment
from the same population: Phase I was conducted be-
tween December 1999 and December 2003 (685 con-
trols and 533 cases) and Phase II was conducted
between October 2006 and June 2011 (567 controls and
509 cases). All subjects enrolled in the study provided
written informed consent as approved by the Institu-
tional Review Boards of the nine medical facilities and
of the Harvard School of Public Health. The participa-
tion rate for controls was 47%. A total of 1107 controls
provided blood upon enrollment during the two phases.HPV16 serology measurement
Serum was separated from venous blood within 12-24 hr of
blood drawing and stored at -80°C. To detect antibodies
against HPV16 L1, E1, E2, E4, E6 and E7 proteins, a gluta-
thione S-transferase capture enzyme-linked immunosorbent
assay (ELISA) was used in combination with fluorescent
bead [16,17]. This assay detects HPV antibodies with high
type specificity and demonstrates assay sensitivity similar to
the “gold-standard” for L1-serology that uses virus-like parti-
cles (VLP) as antigens [17].Additional exposure assessment
All study subjects responded to a self-administered ques-
tionnaire to collect data on demographic characteristics,
medical history, family history of cancer (first-degree rela-
tives), detailed smoking and drinking habits, occupational
history, and residential history. Questionnaires were mailed
to cancer-free control subjects and were returned and
reviewed by study personnel during the in-person visit. In-
formation on the demographic characteristics such as age,
sex, race, education, and income, as well as smoking pack-
years and average drinks per week, have been previously
collected and defined [7].Statistical analysis
Differences in tobacco usage by HPV16 serological status,
controlled for other risk factors and characteristics, were
assessed using ANOVA. Odds ratios (OR) and 95% confi-
dence intervals (CIs) were estimated for smoking status
using unconditional logistic regression and controlling for
known risk factors, including age, sex, race (white or
other), average drinks per week (continuous), education
(less/high school graduate or more), income, number of
sexual partners and age at first intercourse. We created a
variable for any positive serology for oncogenic proteins
(E6/E7) and L1 for HPV type 16. All analyses were con-
ducted in R (Version 2.14) and all tests were two-sided.
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The demographics of the study population are shown in
Table 1, stratified by their HPV16 serological status. Con-
trols who described themselves as non-white and those
whose self-reported annual income was below $50,000
were significantly more likely to have some positive sero-
logical measure of HPV16. Those who reported their age
at first intercourse to be under 18 years old were similarly
significantly more likely to have some detectable positive
serological measure of HPV16. Interestingly, there was no
association of number of sexual partners, education, age,
sex or smoking or drinking history with HPV16 serology
in the unadjusted data.Table 1 Descriptive statistics of subjects by HPV 16 serology
Characteristic All HPV16 negative (N =
Age








At least some college 545 (71.1)
HS diploma or less 201 (26.2)
Income**b, n (%)
< $50,000 242 (31.6)
≥ $50,000 450 (58.7)
Smoking pack-years, n (%)
None 311 (40.5)
First tertile (>0 to 16) 149 (19.4)
Second tertile (16 to 22) 156 (20.3)
Third tertile (22+) 151 (19.7)
Average drinks per week, n (%)
First quartile (<2.2) 193 (25.2)
Second quartile (2.2-5.5) 192 (25.0)
Third quartile (5.5-13.6) 198 (25.8)
Fourth quartile (13.6+) 181 (23.6)
Age of intercourseb, n (%)
<18 years 155 (20.2)
≥18 years 295 (38.5)
Number of sexual partnersa,b, n (%)
<16 165 (46.5)
16+ 165 (46.5)
*Fisher’s exact test used to calculate p-value; **Values do not add to 100% due to m
aPhase 2 only.
bThese characteristics were dichotomized at their median values.In an effort to further examine the relationship of
cigarette smoking with HPV16 serology, we examined dif-
ferent serological measures of HPV16 by cumulative
smoking history (ever vs. never) (Table 2) and adjusted for
age, race, sex, education, and average drinks per week. As
there were missing data for income, age of first inter-
course, and number of sexual partners, the initial models
did not include these variables (Table 2). This analysis
similarly showed no significant association of cumulative
smoking with any individual measure of HPV16 or with a
combined variable indicating any serological response.
Adjustment for age of first intercourse did not appreciably
alter these results.status























Table 2 Logistic regression models of smoking (ever/never) on HPV 16 serology
HPV16 serology measure Smokingb status Number negative/positive ORa (95% CI) p-value
L1 Never 407/30 Ref. -
Ever 617/43 1.04 (0.62, 1.73) 0.89
E1 Never 431/6 Ref.
Ever 653/8 0.92 (0.30, 2.80) 0.88
E2 Never 417/20 Ref.
Ever 639/22 0.74 (0.38, 1.41) 0.34
E4 Never 355/82 Ref.
Ever 546/115 0.95 (0.68, 1.31) 0.74
E6 Never 431/6 Ref. -
Ever 642/19 2.30 (0.88, 6.03) 0.09
E7 Never 421/16 Ref. -
Ever 626/35 1.23 (0.65, 2.32) 0.52
Any HPV16 Never 308/129 Ref. -
Ever 453/208 1.12 (0.85, 1.48) 0.42
aAdjusted for age, race, sex, education, and average drinks per week.
bDefined as “ever” for participants who smoked 100 cigarettes or more (or >0 smoking pack-years and “never” for those who had not (or =0 smoking pack years).
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may be associated with HPV16 presence, we repeated
this analysis (Table 3), stratifying the smokers by current,
former and never smoking. In this analysis there was no
clear significant association of current smoking with any
individual or combined measure of positive HPV16 ser-
ology, although for E6 antibodies there was a borderline
association between former-smoking and positive E6
serology.
Finally, in an effort to examine the possibility that age
was acting as an effect modifier, we repeated the analysis
of the association of cumulative smoking with sero-
logical measures of HPV16, stratifying by the median
age of the control population. For those under the me-
dian age of 61, smoking increased the risk of having
antibodies to the L1 capsid protein, while at the same
time decreasing the risk of being L1 positive in those
over the age of 61 (pinteraction < 0.002; Table 4). Adjusting
for age at first intercourse did not appreciably alter these
findings. In contrast, no similar trend (by age) was ob-
served for smoking associated variation in early gene
protein antibody production (Table 4), although the
point estimates for an association for E1 antibodies were
similar (albeit not statistically significant) to those ob-
served for L1 seropositivity.
Discussion
In our cancer-free control population, income, self-
reported race and age at first intercourse were associated
with a significantly increased likelihood of having some
measure of positive HPV16. This is consistent with a
now large literature –(reviewed in [1,18]). Unlike many
studies, we did not observe a significant association ofnumber of sexual partners with HPV16 positivity,
although there was a small increase in the estimate of
risk in our data (Table 1).
Both the unadjusted and adjusted data showed no
overall association of smoking with any serologic meas-
ure of HPV16 when considering participants of all ages
(range: 22-91 years). However, stratifying by median age
(61 years) revealed an increased risk of antibodies for
HPV16 L1 associated with cigarette smoking in younger
participants and a concomitant decreased risk for the
same measure of HPV16 (antibodies to the L1 capsid
protein) in older smokers. The observed increase in like-
lihood of detecting HPV16 L1 antibodies in the younger
age group is supported by the findings of a recent
population-based cross-sectional study of NHANES
data, in which the authors found that self-report and
biomarkers of recent smoking was associated with in-
creased detection of HPV16 DNA in oral rinse samples
among 18-59 year olds [8]. Age did not modify any other
estimate of risk for positive serological response to
HPV16; in particular, there was minimal indication of
any modification of risk of detection of antibodies to any
of the early gene proteins.
The interpretation of positive HPV16 serology can be
complex. The detection of antibodies to the capsid pro-
teins is most often thought to reflect exposure to the
virus, while antibodies to the early genes reflect an active
infection, since production of the early gene proteins re-
quires virus-driven cellular mitosis. Hence, the preva-
lence of positive HPV16 L1 serology is considerably
higher than that of the early genes (in our data and in
that reported by others) [19-21]. In addition (and con-
sistent with this interpretation of these biomarkers),


















L1 Never 241/11 Ref. - 166/19 Ref. -
Ever 264/29 3.05 (1.42, 6.56) 0.004 353/14 0.31 (0.15, 0.66) 0.003
E1 Never 251/1 Ref. - 180/5 Ref. -
Ever 288/5 4.38 (0.46, 42.1) 0.20 365/3 0.29 (0.07, 1.31) 0.11
E2 Never 244/8 Ref. - 173/12 Ref. -
Ever 285/8 0.85 (0.29, 2.48) 0.77 354/15 0.65 (0.29, 1.48) 0.30
E4 Never 204/48 Ref. - 151/34 Ref -
Ever 240/53 0.94 (0.59, 1.50) 0.80 306/62 0.95 (0.59, 1.53) 0.83
E6 Never 248/4 Ref. - 183/2 Ref. -
Ever 283/10 2.44 (0.70, 8.43) 0.16 359/9 2.85 (0.58, 13.9) 0.19
E7 Never 243/9 Ref. - 178/7 Ref. -
Ever 283/10 1.00 (0.37, 2.71) 0.99 343/25 1.50 (0.62, 3.64) 0.37
Any HPV 16 Never 179/73 Ref. - 129/56 Ref. -
Ever 199/94 1.26 (0.85, 1.87) 0.26 254/114 1.00 (0.67, 1.48) 0.98
aAdjusted for age, race, sex, education, and average drinks per week.
Table 3 HPV16 serology stratified by smoking status
HPV16 serology measure Smokingb status Number negative/positive ORa (95% CI) p-value
L1 Never 407/30 Ref. -
Former 472/34 1.11 (0.65, 1.90) 0.70
Current 130/9 0.92 (0.41, 2.07) 0.85
E1 Never 431/6 Ref.
Former 501/6 0.87 (0.26, 2.87) 0.82
Current 137/2 1.25 (0.23, 6.68) 0.80
E2 Never 417/20 Ref.
Former 490/17 0.73 (0.37, 1.46) 0.38
Current 135/4 0.64 (0.21, 1.98) 0.44
E4 Never 355/82 Ref.
Former 415/92 1.01 (0.71, 1.42) 0.97
Current 117/22 0.82 (0.48, 1.40) 0.46
E6 Never 431/6 Ref. -
Former 491/16 2.53 (0.95, 6.81) 0.06
Current 136/3 1.72 (0.40, 7.31) 0.46
E7 Never 421/16 Ref. -
Former 478/29 1.35 (0.70, 2.61) 0.36
Current 133/6 0.94 (0.35, 2.54) 0.90
Any HPV 16 Never 308/129 Ref. -
Former 339/168 1.23 (0.92, 1.65) 0.16
Current 101/38 0.86 (0.55, 1.34) 0.50
aAdjusted for age, race, sex, education, and average drinks per week.
bSmoking status defined by smoking pack-years. Participants who reported zero smoking pack-years were considered to have never smoked. Participants who
reported >0 smoking pack years were divided into current and former status based on whether they reported to be current smokers upon entry into the study.
Kelsey et al. BMC Infectious Diseases  (2015) 15:8 Page 5 of 7
Kelsey et al. BMC Infectious Diseases  (2015) 15:8 Page 6 of 7many studies have shown that HNSCC risk is consider-
ably greater for those with evidence of antibodies to
early genes (particularly E6 and E7) [2,22]. In this con-
text, our data suggests that cigarette smoking may mod-
ify either the exposure to the HPV16 virus, the immune
response to exposure, or both of these, while not affect-
ing the active formation of infections.
One explanation of our findings could be that the
younger smokers were exposed to HPV16 quite often,
while older smokers were less exposed to the virus. This
is possible, of course, and it has been reported that
smoking is associated with a enhanced risk-taking be-
havior [23]. We attempted to control for this by adjust-
ing for age at first intercourse and number of sexual
partners in our models. There may be residual con-
founding that is responsible for the finding of age-
associated differences in HPV16 L1 antibodies modified
by smoking.
It also is possible that smoking produces microtrauma,
increasing opportunities for entry of the virus. However,
for this to be consistent with our data, smoking induced
microtrauma would need to be age-associated, and be
worse in younger smokers. This is unlikely, since smok-
ing is associated with significant dental pathology and
this is known to worsen with age and continued smok-
ing, increasing, rather than decreasing, opportunities for
viral entry.
Alternatively, smoking-related variation in the ability
of an individual to produce antibodies after HPV16 ex-
posure (an enhanced response to HPV associated with
smoking in younger people, with waning immunity in
older smokers after prior exposure) could explain our
findings. It is known that smoking alters leukocyte pro-
file [24] and smokers have been shown to respond to
vaccination with production of both more and less anti-
body under differing antigenic challenge [25,26]. If
HPV16 exposure is relatively stable across the popula-
tion, changes in the immune response to HPV16 that
are associated with smoking (enhanced antibody produc-
tion in younger smokers and less antibody response in
older smokers) could produce our results. Of course, an
altered immune response could also lead to less viral
clearance, which would likely enhance the oncogenic ef-
fects of the virus. We cannot differentiate between these
possibilities, although our data would suggest that to-
bacco smoking does alter either exposure or immune re-
sponse (or both) to HPV16 differentially by age.
It is important to also note that our data provide no
clear indication that active HPV16 infection (as repre-
sented by an immune response to the early gene pro-
teins) is altered by smoking, at any age. At the same
time, our study is limited by the small numbers of
disease-free participants who were seropositive for the
early gene proteins. While our findings for antibodies tothe capsid proteins are robust, it is less clear that the
findings for antibodies to the early genes are stable.
Hence, while our data suggest that smoking does not en-
hance active infection, we believe that it is important to
revisit the question of the relationship of tobacco use
with HPV16 early gene positivity in large numbers of
disease free individuals, as the rate of clearance of the
virus may be affected by smoking.
Conclusions
In summary, our data suggest that HPV16 exposure is
modified by age and smoking. It is not clear whether the
association of HPV16 capsid antigen positivity with
smoking is also accompanied by an alteration in the
pathological process of infection. It is becoming crucially
important to assess whether smoking is able to impact
cellular response to viral infection and the progress to-
ward virally driven disease.
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